We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

175 hedge funds and large institutions have $650M invested in Intercept Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 58 increasing their positions, 52 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 52

5% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 37

1% less funds holding

Funds holding: 177175 (-2)

25% less call options, than puts

Call options by funds: $36M | Put options by funds: $47.8M

45% less capital invested

Capital invested by funds: $1.18B → $650M (-$528M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
175
Holders Change
-2
Holders Change %
-1.13%
% of All Funds
3.1%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
35
Increased
58
Reduced
52
Closed
37
Calls
$36M
Puts
$47.8M
Net Calls
-$11.8M
Net Calls Change
-$7.54M
Name Holding Trade Value Shares
Change
Change in
Stake
AI
76
Atom Investors
Texas
$498K -$1.39M -41,896 -68%
AWM
77
AE Wealth Management
Kansas
$477K +$156K +4,699 +32%
ECM
78
ExodusPoint Capital Management
New York
$468K +$627K +18,929 New
VEA
79
Virtus ETF Advisers
New York
$466K +$367K +11,075 +142%
ACM
80
AlphaCrest Capital Management
New York
$465K +$352K +10,632 +130%
QIM
81
Quantitative Investment Management
Virginia
$428K -$456K -13,762 -44%
Stifel Financial
82
Stifel Financial
Missouri
$422K +$337K +10,155 +146%
UBS Group
83
UBS Group
Switzerland
$421K -$54.4K -1,641 -9%
BAM
84
Blueshift Asset Management
New Jersey
$420K +$563K +16,997 New
MC
85
Maverick Capital
Texas
$401K +$538K +16,242 New
Manulife (Manufacturers Life Insurance)
86
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$390K +$15.7K +473 +3%
D.E. Shaw & Co
87
D.E. Shaw & Co
New York
$370K -$1.53M -46,318 -76%
Legal & General Group
88
Legal & General Group
United Kingdom
$370K -$1.39K -42 -0.3%
VOYA Investment Management
89
VOYA Investment Management
Georgia
$364K +$115K +3,469 +31%
BIM
90
Bogle Investment Management
Massachusetts
$348K -$1.86M -56,206 -80%
WDC
91
Woodward Diversified Capital
California
$348K +$467K +14,083 New
PCM
92
Prelude Capital Management
New York
$342K +$458K +13,830 New
State Board of Administration of Florida Retirement System
93
State Board of Administration of Florida Retirement System
Florida
$325K -$23.9K -720 -5%
Bank of Montreal
94
Bank of Montreal
Ontario, Canada
$324K -$229K -6,899 -40%
UBS AM
95
UBS AM
Illinois
$312K -$4.9M -147,885 -92%
AG
96
Aperio Group
California
$311K +$84.5K +2,551 +25%
VRS
97
Virginia Retirement Systems
Virginia
$311K +$418K +12,600 New
CM
98
Caption Management
Oklahoma
$296K -$200K -6,029 -33%
MIM
99
MetLife Investment Management
New Jersey
$277K
FAM
100
Formidable Asset Management
Ohio
$274K +$331K +10,000 New

ICPT Hedge Fund Activity: Q4 2020 in Review

175 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2020, worth a combined $650M — down 45% from $1.18B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of ICPT and 35 opened new positions — a net loss of 2 holders — while 52 trimmed existing stakes and 58 added.

The largest buyer was State Street, adding an estimated $28.5M. The largest seller was Boxer Capital, exiting entirely with an estimated $48.8M sold.

  • 175 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2020, down from 177 in Q3 2020.
  • Funds reported $650M of Intercept Pharmaceuticals, Inc. stock for Q4 2020, down 45% quarter-over-quarter.
  • 35 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2020 and 37 closed out, a net change of -2 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2020 was State Street, an estimated $28.5M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q4 2020 was Boxer Capital, an estimated $48.8M sold.

Based on aggregated 13F filings for Q4 2020.